

[Handwritten signature]



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of James Martin LENHARD


Serial No.: 09/889,471

Art Unit: 1648

Filing Date: July 17, 2001

Examiner: Parkin, Jeffrey S.

For: *Methods Of Screening Protease Inhibitors,
Of Inducing Mice Susceptible To HIV Protease
Inhibitor-Induced Dyslipidemia, and Genes
Associated Therewith*



Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed
☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
☒ A copy of the European Search Report which issued on European Application No. 00905651.6 is submitted herewith. All of the publications cited in the European Search Report are listed on the attached form PTO-1449.

- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☒ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: October 21, 2004


Marjorie J. Pfeiffer
Marjorie J. Pfeiffer

- ☒ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Michael M. Conger
Attorney of Record
Registration No. 43,562

Date: October 21, 2004
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-2474
Facsimile: (919) 483-7988

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT
ATTORNEY DOCKET NO.

PU3610USw

SERIAL NO.

09/889,471

APPLICANT

James Martin LENHARD

FILING DATE

July 17, 2001

GROUP

1648

U.S. PATENT DOCUMENTS

Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page ____

FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Subclass	Translation Yes No

Continue on page ____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

1.	Collins et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety," <i>Journal of Medicinal and Pharmaceutical Chemistry</i> 41:5037-5054 (1998).
2.	Gagnon et al., "Protease inhibitors and adipocyte differentiation in cell culture," <i>Lancet</i> 352(9133):1032 (Sep. 1998).
3.	Henke et al., "n-(2-benzoylphenyl)-L-tyrosine PPAR-GAMMA agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents," <i>Journal of Medicinal Chemistry</i> 41(25):5020-5036 (1998).
4.	Jain et al., "Metabolic complications associated with antiretroviral therapy," <i>Antiviral Research</i> 51(3):151-177 (Sep. 2001).
5.	James, "Lipodystrophy: Glaxo researchers suggest mechanisms, publish data," <i>AIDS Treatment News</i> 315:1-4 (Mar. 1999).
6.	Kliwer et al., "Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferators-activated receptors alpha and gamma," <i>Proc. Nat'l. Acad. Sci. USA</i> 9(94):4318-4323 (Apr. 1997).
7.	Lenhard et al., "Effects of troglitazone and metformin on glucose and lipid metabolism," <i>Biochemical Pharmacology</i> 54(7):801-808 (1997).
8.	Lenhard et al., "Indinavir enhances retinoic acid signaling: nelfinavir, saquinavir, and ritonavir inhibit retinoid effects in vitro," <i>Aidsline</i> (Jan. 31, 1999 - Feb. 4, 1999).
9.	Lenhard et al., "Conf. Retroviruses opportunistic infect," abstract 666, Online! (Jan. 31, 1999 - Feb. 4, 1999)
10.	Nichols et al., "Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain," <i>Analytical Biochemistry</i> 257(2):112-119 (Mar. 1998).
11.	Paulik et al., "Thiazolidinediones inhibit alkaline phosphatase activity while increasing expression of uncoupling protein, deiodinase, and increasing mitochondrial mass in C3H10T1/2 cells," <i>Cell and Tissue Research</i> 290(1):79-87 (1997).
12.	Ye et al., "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared with humans," <i>AIDS</i> 12(16):2236-2237 (Nov. 1998).

Continue on page ____

EXAMINER
DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

